FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.